Abdel Nasser Hosein1, Gita Dangol2, Takashi Okumura2, Jason Roszik3, Kimal Rajapakshe2, Megan Siemann2, Mohamed Zaid4, Bidyut Ghosh2, Maria Monberg2, Paola A Guerrero2, Aatur Singhi5, Cara L Haymaker2, Hans Clevers6, Lotfi Abou-Elkacem2, Sonja M Woermann2, Anirban Maitra7. 1. Department of Translational Molecular Pathology, Ahmad Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Internal Medicine, Division of Hematology and Oncology, The University of Texas Southwestern Medical Center, Dallas, Texas; Advocate Aurora Health, Vince Lombardi Cancer Clinic, Sheboygan, Wisconsin. 2. Department of Translational Molecular Pathology, Ahmad Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Melanoma Medical Oncology Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 6. Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, University Medical Center Utrecht and Princess Maxima Center, Utrecht, the Netherlands. 7. Department of Translational Molecular Pathology, Ahmad Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: amaitra@mdanderson.org.
Abstract
BACKGROUND & AIMS: RNF43 is an E3 ubiquitin ligase that is recurrently mutated in pancreatic ductal adenocarcinoma (PDAC) and precursor cystic neoplasms of the pancreas. The impact of RNF43 mutations on PDAC is poorly understood and autochthonous models have not been characterized sufficiently. In this study, we describe a genetically engineered mouse model (GEMM) of PDAC with conditional expression of oncogenic Kras and deletion of the catalytic domain of Rnf43 in exocrine cells. METHODS: We generated Ptf1a-Cre;LSL-KrasG12D;Rnf43flox/flox (KRC) and Ptf1a-Cre; LSL-KrasG12D (KC) mice and animal survival was assessed. KRC mice were sacrificed at 2 months, 4 months, and at moribund status followed by analysis of pancreata by single-cell RNA sequencing. Comparative analyses between moribund KRC and a moribund Kras/Tp53-driven PDAC GEMM (KPC) was performed. Cell lines were isolated from KRC and KC tumors and interrogated by cytokine array analyses, ATAC sequencing, and in vitro drug assays. KRC GEMMs were also treated with an anti-CTLA4 neutralizing antibody with treatment response measured by magnetic response imaging. RESULTS: We demonstrate that KRC mice display a marked increase in incidence of high-grade cystic lesions of the pancreas and PDAC compared with KC. Importantly, KRC mice have a significantly decreased survival compared with KC mice. Using single-cell RNA sequencing, we demonstrated that KRC tumor progression is accompanied by a decrease in macrophages, as well as an increase in T and B lymphocytes, with evidence of increased immune checkpoint molecule expression and affinity maturation, respectively. This was in stark contrast to the tumor immune microenvironment observed in the KPC PDAC GEMM. Furthermore, expression of the chemokine CXCL5 was found to be specifically decreased in KRC cancer cells by means of epigenetic regulation and emerged as a putative candidate for mediating the unique KRC immune landscape. CONCLUSIONS: The KRC GEMM establishes RNF43 as a bona fide tumor suppressor gene in PDAC. This GEMM features a markedly different immune microenvironment compared with previously reported PDAC GEMMs and puts forth a rationale for an immunotherapy approach in this subset of PDAC cases.
BACKGROUND & AIMS: RNF43 is an E3 ubiquitin ligase that is recurrently mutated in pancreatic ductal adenocarcinoma (PDAC) and precursor cystic neoplasms of the pancreas. The impact of RNF43 mutations on PDAC is poorly understood and autochthonous models have not been characterized sufficiently. In this study, we describe a genetically engineered mouse model (GEMM) of PDAC with conditional expression of oncogenic Kras and deletion of the catalytic domain of Rnf43 in exocrine cells. METHODS: We generated Ptf1a-Cre;LSL-KrasG12D;Rnf43flox/flox (KRC) and Ptf1a-Cre; LSL-KrasG12D (KC) mice and animal survival was assessed. KRC mice were sacrificed at 2 months, 4 months, and at moribund status followed by analysis of pancreata by single-cell RNA sequencing. Comparative analyses between moribund KRC and a moribund Kras/Tp53-driven PDAC GEMM (KPC) was performed. Cell lines were isolated from KRC and KC tumors and interrogated by cytokine array analyses, ATAC sequencing, and in vitro drug assays. KRC GEMMs were also treated with an anti-CTLA4 neutralizing antibody with treatment response measured by magnetic response imaging. RESULTS: We demonstrate that KRC mice display a marked increase in incidence of high-grade cystic lesions of the pancreas and PDAC compared with KC. Importantly, KRC mice have a significantly decreased survival compared with KC mice. Using single-cell RNA sequencing, we demonstrated that KRC tumor progression is accompanied by a decrease in macrophages, as well as an increase in T and B lymphocytes, with evidence of increased immune checkpoint molecule expression and affinity maturation, respectively. This was in stark contrast to the tumor immune microenvironment observed in the KPC PDAC GEMM. Furthermore, expression of the chemokine CXCL5 was found to be specifically decreased in KRC cancer cells by means of epigenetic regulation and emerged as a putative candidate for mediating the unique KRC immune landscape. CONCLUSIONS: The KRC GEMM establishes RNF43 as a bona fide tumor suppressor gene in PDAC. This GEMM features a markedly different immune microenvironment compared with previously reported PDAC GEMMs and puts forth a rationale for an immunotherapy approach in this subset of PDAC cases.
Authors: Joanne Leung; Luis A Rojas; Jennifer Ruan; John Alec Moral; Julia Zhao; Zachary Sethna; Anita Ramnarain; Billel Gasmi; Murali Gururajan; David Redmond; Gokce Askan; Umesh Bhanot; Ela Elyada; Youngkyu Park; David A Tuveson; Mithat Gönen; Steven D Leach; Jedd D Wolchok; Ronald P DeMatteo; Taha Merghoub; Vinod P Balachandran Journal: Nature Date: 2020-02-19 Impact factor: 49.962
Authors: Mohan Bolisetty; Pasquale Laise; William F Flynn; Ela Elyada; Elise T Courtois; Richard A Burkhart; Jonathan A Teinor; Pascal Belleau; Giulia Biffi; Matthew S Lucito; Santhosh Sivajothi; Todd D Armstrong; Dannielle D Engle; Kenneth H Yu; Yuan Hao; Christopher L Wolfgang; Youngkyu Park; Jonathan Preall; Elizabeth M Jaffee; Andrea Califano; Paul Robson; David A Tuveson Journal: Cancer Discov Date: 2019-06-13 Impact factor: 39.397
Authors: Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian Journal: Cancer Res Date: 2014-06-01 Impact factor: 12.701
Authors: Yu Zhu; John M Herndon; Dorothy K Sojka; Ki-Wook Kim; Brett L Knolhoff; Chong Zuo; Darren R Cullinan; Jingqin Luo; Audrey R Bearden; Kory J Lavine; Wayne M Yokoyama; William G Hawkins; Ryan C Fields; Gwendalyn J Randolph; David G DeNardo Journal: Immunity Date: 2017-08-15 Impact factor: 31.745
Authors: Caitlin A McIntyre; Sharon A Lawrence; Allison L Richards; Joanne F Chou; Winston Wong; Marinela Capanu; Michael F Berger; Mark T A Donoghue; Kenneth H Yu; Anna M Varghese; David P Kelsen; Wungki Park; Vinod P Balachandran; T Peter Kingham; Michael I D'Angelica; Jeffrey A Drebin; William R Jarnagin; Christine A Iacobuzio-Donahue; Peter J Allen; Eileen M O'Reilly Journal: Cancer Date: 2020-06-23 Impact factor: 6.860
Authors: Eliana Amato; Marco Dal Molin; Andrea Mafficini; Jun Yu; Giuseppe Malleo; Borislav Rusev; Matteo Fassan; Davide Antonello; Yoshihiko Sadakari; Paola Castelli; Giuseppe Zamboni; Anirban Maitra; Roberto Salvia; Ralph H Hruban; Claudio Bassi; Paola Capelli; Rita T Lawlor; Michael Goggins; Aldo Scarpa Journal: J Pathol Date: 2014-07 Impact factor: 7.996
Authors: Beth A Helmink; Sangeetha M Reddy; Jianjun Gao; Shaojun Zhang; Rafet Basar; Rohit Thakur; Keren Yizhak; Moshe Sade-Feldman; Jorge Blando; Guangchun Han; Vancheswaran Gopalakrishnan; Yuanxin Xi; Hao Zhao; Rodabe N Amaria; Hussein A Tawbi; Alex P Cogdill; Wenbin Liu; Valerie S LeBleu; Fernanda G Kugeratski; Sapna Patel; Michael A Davies; Patrick Hwu; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Reetakshi Arora; Scott Woodman; Emily Z Keung; Pierre-Olivier Gaudreau; Alexandre Reuben; Christine N Spencer; Elizabeth M Burton; Lauren E Haydu; Alexander J Lazar; Roberta Zapassodi; Courtney W Hudgens; Deborah A Ledesma; SuFey Ong; Michael Bailey; Sarah Warren; Disha Rao; Oscar Krijgsman; Elisa A Rozeman; Daniel Peeper; Christian U Blank; Ton N Schumacher; Lisa H Butterfield; Monika A Zelazowska; Kevin M McBride; Raghu Kalluri; James Allison; Florent Petitprez; Wolf Herman Fridman; Catherine Sautès-Fridman; Nir Hacohen; Katayoun Rezvani; Padmanee Sharma; Michael T Tetzlaff; Linghua Wang; Jennifer A Wargo Journal: Nature Date: 2020-01-15 Impact factor: 69.504